This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bachega, T. A. S. S. Articles by Mendonca, B. B. Search for Related Content PubMed PubMed Citation Articles by Bachega, T. A. S. S. Articles by Mendonca, B. B.

Variable ACTH-Stimulated 17-Hydroxyprogesterone Values in 21-Hydroxylase Deficiency Carriers Are Not Related to the Different CYP21 Gene Mutations

Unidade de Endocrinologia do Desenvolvimento e Laboratório de Hormônios e Genética Molecular, LIM/42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403–900, Brazil

Address all correspondence and requests for reprints to: Berenice B. Mendonca, M.D., Hospital das Clínicas, Faculdade de Medicina da Universidade de Saõ Paulo, Disciplina de Endocrinologia, Caixa Postal 3671, São Paulo, 01060-970, Brasil. E-mail: beremen{at}usp.br

Abstract

The currently used cutoff level for ACTH-stimulated 17- hydroxyprogesterone (17OHP) for the diagnosis of the nonclassical (NC) form of 21-hydroxylase deficiency (21OHD), established before molecular studies, is based on the mean + 2 SD of 17OHP levels of obligate heterozygotes. However, carriers of CYP21 mutations present variable ACTH-stimulated 17OHP levels, ranging from normal values up to 30 nmol/liter. The aim of this study was to determine whether ACTH-stimulated 17OHP levels in obligate carriers for 21OHD would be correlated with the impairment of the enzyme activity caused by these mutations, which would affect the 17OHP cutoff level for the diagnosis of the NC form. Fifty-nine parents of patients with the classical and NC forms of 21OHD had their DNA screened for the mutations found in the index case and were divided into three mutation groups according to the impairment of enzyme activity (A = 0%, B = 3%, and C > 20%). All parents carried mutations in one allele (29 of group A, 9 of group B, and 21 of group C). Blood samples were collected at baseline condition and 60 min after ACTH (250 µg iv) to measure 17OHP levels. The levels among groups A, B, and C were compared using the Kruskall Wallis test. ACTH-stimulated 17OHP levels identified 39% of the carriers (9 in group A, 2 in group B and 12 in group C). The mean ± SD basal 17OHP levels in groups A, B, and C were: 2.94 ± 1.89, 1.77 ± 0.81 and 3.90 ± 2.43 nmol/liter, respectively (P > 0.05) and for ACTH-stimulated levels were 12.6 ± 7.2, 13.2 ± 12.9 and 16.8 ± 7.8 nmol/liter, respectively (P > 0.05). Two carriers presented ACTH-stimulated 17OHP levels between 30 and 45 nmol/liter and their entire CYP21 sequencing revealed only one mutation in heterozygous state indicating that the current cutoff level might overestimate the diagnosis of the NC form. We conclude that the variable ACTH-stimulated 17-OHP levels in carriers are not related to CYP21 gene mutations with different impairment of enzyme activity.

This article has been cited by other articles:

				M. Bidet, C. Bellanne-Chantelot, M.-B. Galand-Portier, V. Tardy, L. Billaud, K. Laborde, C. Coussieu, Y. Morel, C. Vaury, J.-L. Golmard, et al. Clinical and Molecular Characterization of a Cohort of 161 Unrelated Women with Nonclassical Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and 330 Family Members J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1570 - 1578. [Abstract] [Full Text] [PDF]

				L. G. Gomes, N. Huang, V. Agrawal, B. B. Mendonca, T. A. S. S. Bachega, and W. L. Miller The Common P450 Oxidoreductase Variant A503V Is Not a Modifier Gene for 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2913 - 2916. [Abstract] [Full Text] [PDF]

				R. S. Araujo, B. B. Mendonca, A. S. Barbosa, C. J. Lin, J. A. M. Marcondes, A. E. C. Billerbeck, and T. A. S. S. Bachega Microconversion between CYP21A2 and CYP21A1P Promoter Regions Causes the Nonclassical Form of 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 4028 - 4034. [Abstract] [Full Text] [PDF]

				S. M. Baumgartner-Parzer, P. Nowotny, G. Heinze, W. Waldhausl, and H. Vierhapper Carrier Frequency of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in a Middle European Population J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 775 - 778. [Abstract] [Full Text] [PDF]

				N. M. M. L. Stikkelbroeck, L. H. Hoefsloot, I. J. de Wijs, B. J. Otten, A. R. M. M. Hermus, and E. A. Sistermans CYP21 Gene Mutation Analysis in 198 Patients with 21-Hydroxylase Deficiency in The Netherlands: Six Novel Mutations and a Specific Cluster of Four Mutations J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3852 - 3859. [Abstract] [Full Text] [PDF]